$VCEL

SIEGAL JONATHAN sold $123K of VCEL

SIEGAL JONATHAN (Principal Accounting Officer) sold 2,732 shares of Vericel Corp (VCEL) at $44.90 ($0.12M total) across 2 trades on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SIEGAL JONATHAN
Published Jun 30, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$VCEL
Neutral
medium confidence
Mentioned
$VCEL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VCELNeutralLow
01

Why it matters

The newest fact is the specific sale size, price ($44.90), and that it was executed under a pre-arranged 10b5-1 plan; no new business developments are included.

02

Market read

Traders may monitor insider activity, but 10b5-1 sales typically carry limited incremental information versus fundamental catalysts.

03

What to watch

The article doesn’t state whether other insiders sold/bought around the same time, nor does it provide any new company performance information.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-06-30; sale executed 2026-06-26

Background

The article is an SEC Form 4 insider transaction disclosure for Vericel Corp (VCEL).

Company-level read

Ticker impact

$VCELNeutralMedium confidence
Context

Vericel insider Form 4 shows principal accounting officer sold 2,732 shares at $44.90 on a 10b5-1 plan, totaling $122,666.80.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change in the text.

Market effects

No sector read-through; this is a single-company insider transaction with no new clinical/regulatory datapoints.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Vericel Corp

    Subject of the Form 4 insider sale disclosure.

  • SIEGAL JONATHAN

    Principal Accounting Officer who sold shares under a 10b5-1 plan.

Related articles

$VCELMedAI 8/10

Vericel Q2 Earnings Call Highlights

Vericel (NASDAQ: VCEL) reported Q2 earnings call updates. Burn Care revenue rose 22% to about $12M, with Epicel at $10.4M and NexoBrid above $1.5M. 2026 guidance was raised to $330M-$340M total revenue, MACI to $284M-$290M, Burn Care to $46M-$50M, and Q3 revenue to $76.5M-$78.5M. Board authorized a $200M buyback.

$VCELHigh

Vericel Corp (VCEL): Results of Operations and Financial Condition

Vericel Corp (VCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Vericel Corporation 25 Blue Sky Drive Burlington, MA 01803 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Sh